Fox Chase Cancer Center | Strategic Alliance Partners

July 25, 2018

Jessica Bauman, MD, addresses current and emerging therapeutic options for patients with BRAF, ROS1, and RET abnormalities in non–small cell lung cancer.

July 04, 2018

Jessica Bauman, MD, assistant professor, Department of Hematology/Oncology, associate program director, Hematology/Oncology Fellowship Training Program, Fox Chase Cancer Center, discusses treatments for patients with BRAF-mutant non–small cell lung cancer (NSCLC).

June 11, 2018

Although testing for some genetic defects has been incorporated into the treatment paradigm, the clinical utility of up-front tumor sequencing that would yield wide-ranging information has not yet been established.

February 13, 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses recent trials in kidney cancer.

January 16, 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses choosing a checkpoint inhibitor in bladder cancer.

December 12, 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the approved checkpoint inhibitors for the second-line treatment of patients with bladder cancer.

October 31, 2017

Elizabeth Plimack, MD, discusses the management of locally advanced urothelial carcinoma and the ongoing trials that are investigating treatments for this patient population.

October 26, 2017

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses the role of surgery in kidney cancer.

October 23, 2017

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses immunotherapy in metastatic renal cell carcinoma.

October 21, 2017

Daniel M. Geynisman, MD, discusses remaining challenges in the landscape of RCC, despite progress with systemic therapies and the pivotal ongoing studies combining immunotherapy and targeted therapy.

October 13, 2017

Robert G. Uzzo, MD, discusses recent guidelines that have impacted clinical practice and ongoing biomarker research in the field of kidney cancer.

October 04, 2017

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses pressing unmet needs for patients with kidney cancer.

October 03, 2017

Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses determining treatments for patients with renal cell carcinoma (RCC).

August 15, 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, shares the challenges with the FDA-approved immunotherapy agents for the treatment of patients with bladder cancer.

August 01, 2017

Alexander Kutikov, MD, has been appointed the new chief of the Division of Urologic Oncology at Fox Chase Cancer Center.

July 27, 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the phase Ib trial of epacodostat and pembrolizumab (Keytruda) in patients with urothelial carcinoma.

July 27, 2017

Elizabeth Plimack, MD, recaps recent advances in bladder cancer and discusses the need for diverse approaches to further improve patient outcomes.

January 20, 2017

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses how physicians can help patients with lung cancer feel more comfortable reporting adverse events (AEs) associated with immunotherapy.

October 06, 2016

Lori Rink, PhD, discusses the groundbreaking impact of imatinib (Gleevec) in gastrointestinal stromal tumors, the heterogeneity of the disease and its impact on personalizing treatment, and emerging therapies in the field.

October 05, 2016

Hossein Borghaei, DO, provides additional insight on checkpoint inhibitors, determining patient selection, and how these therapies will continue to significantly impact the treatment landscape in non–small cell lung cancer for years to come.